Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Syngene InternationalNSE:SYNGENE +1.77%81 PEG Ratio is 7.59 as of Jul. 28, 2026, which is 60% above its 10-year median of 4.73. GuruFocus rates NSE:SYNGENE with a GF Score™ of 81/100 and a GF Value™ of ₹771.56 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 36 Medical Diagnostics & Research companies, Syngene International ranks worse than 86.11% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Syngene International's PEG Ratio or its related term are showing as below:
NSE:SYNGENE'
s PEG Ratio Range Over the Past 10 Years
Min: 1.1 Med: 4.73 Max: 8.36
Current: 7.59
During the past 13 years, Syngene International's highest PEG Ratio was 8.36. The lowest was 1.10. And the median was 4.73.
NSE:SYNGENE's PEG Ratio is ranked worse than 86.11% of 36
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.285
vs NSE:SYNGENE: 7.59
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Syngene International (NSE:SYNGENE) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:SYNGENE vs TMO, DHR, IDXX: PEG Ratio Comparison
For the Diagnostics & Research subindustry, Syngene International's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Syngene International PEG Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Syngene International's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Syngene International's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Syngene International (NSE:SYNGENE) has a PEG Ratio of 7.59 as of Jul. 28, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Syngene International and its competitors. This is 60% above median its historical median of 4.73. Over the past decade, Syngene International's PEG Ratio has ranged from 1.10 to 8.36. According to the industry distribution chart, Syngene International ranks #31 out of 36 companies in the Medical Diagnostics & Research industry, placing it in the top 86.1%.
Is Syngene International's PEG Ratio too high?
Syngene International's current PEG Ratio of 7.59 is 60% above median its 10-year median of 4.73. Over the past 10 years, this metric has ranged from a low of 1.10 to a high of 8.36. The Medical Diagnostics & Research industry median PEG Ratio is 2.29. Syngene International's value of 7.59 is 232.2% above this industry median. Based on the distribution chart, Syngene International ranks #31 out of 36 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Syngene International has a GF Score™ of 81/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Syngene International's PEG Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Syngene International ranks #31 out of 36 companies for PEG Ratio. This places Syngene International in the lower half of its industry. The industry median PEG Ratio is 2.29. Syngene International's value of 7.59 is 232.2% above this benchmark. Historically, Syngene International's own PEG Ratio has ranged from 1.10 to 8.36 over the past decade. While the company's 10-year median is 4.73 vs. the industry median of 2.29, Syngene International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Medical Diagnostics & Research company?
The median PEG Ratio among Medical Diagnostics & Research companies is 2.29, based on 36 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Syngene International's current PEG Ratio of 7.59 is 232.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Syngene International and its competitors. For the Medical Diagnostics & Research industry, the median PEG Ratio is 2.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Syngene International's current PEG Ratio is 7.59, which is 60% above median its own 10-year median of 4.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syngene International stock overvalued right now?
Based on GuruFocus' analysis, Syngene International (NSE:SYNGENE) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹771.56, compared to a current price of ₹413.85 — trading 46.4% below its estimated fair value. The current PEG Ratio is 7.59, which is 60% above median its 10-year median of 4.73 and 232.2% above the Medical Diagnostics & Research industry median of 2.29. Syngene International's overall GF Score™ is 81/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Syngene International (NSE:SYNGENE), the current PEG Ratio is 7.59 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Syngene International (NSE:SYNGENE) Overvalued in 2026?
Based on GuruFocus' analysis, Syngene International stock appears to be undervalued.
The current stock price of ₹413.85 is trading 46.4% below its estimated GF Value™ of ₹771.56.
GuruFocus considers Syngene International to be Significantly Undervalued.
Key valuation signals for NSE:SYNGENE:
PEG Ratio: 7.59 (60% above median its 10-year median of 4.73)
GF Value™: ₹771.56 vs. price of ₹413.85 (46.4% below fair value)
Industry Position: 232.2% above the Medical Diagnostics & Research median (#31 of 36)
No single metric tells the full story. See the NSE:SYNGENE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Syngene International Ltd is a contract research and manufacturing organization in India. It supports research and development programs, from lead generation to clinical and commercial supplies. The Company is engaged in a single operating segment of providing contract research and manufacturing services. The company operates in India, the United States of America and other countries, of which a majority of the revenue is derived from the USA. The company receives revenue by providing contract research and manufacturing services. It offers services such as Oligonucleotide synthesis, Bioinformatics, Clinical development services, polymer research, chemical development, safety assessment, discovery chemistry, discovery biology, and others.
81GF Score
Get the complete analysis for NSE:SYNGENE
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SYNGENE has been successfully added to your 
